# EyePoint Announces Participation at Upcoming Investor Conferences
Canonical URL: https://biopharmsignal.com/news/EYPT/eyepoint-announces-participation-at-upcoming-investor-conferences-cef7e0be
Ticker: EYPT
Company: EyePoint Pharmaceuticals
Source: EyePoint Pharmaceuticals
Published: 2026-05-19 11:00 EST
## Summary

EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative...

## Article Body
EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company management will participate at the following upcoming conferences:

Stifel 2026 Virtual Ophthalmology Forum Forum: Fireside Chat Date: May 26, 2026 Time: 9:00 am ET

Jefferies Global Healthcare Conference Forum: Fireside Chat Date: June 3, 2026 Time: 4:55 p.m. ET

Goldman Sachs 47 th Annual Global Healthcare Conference Forum: Fireside Chat Date: June 9, 2026 Time: 11:20 a.m. ET

A webcast and subsequent archived replay of each fireside chat may be accessed via the Investors section of the Company website at www.eyepoint.bio .

About EyePoint

EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU ™ , is an innovative investigational sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, in next-generation bioerodible Durasert E ™ technology. Supported by robust safety and efficacy data across multiple clinical trials and indications, DURAVYU is currently being evaluated in Phase 3 pivotal trials for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Topline data is expected for wet AMD beginning in mid-2026.

The Company is committed to partnering with the retina community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation.

EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.

Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.

DURAVYU ™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.

Investors:

Tanner Kaufman / Jenni Lu FTI Consulting tanner.kaufman@fticonsulting.com / jenni.lu@fticonsulting.com

Media:

Helen O’Gorman FTI Consulting helen.ogorman@fticonsulting.com
## Recent Company News
- 2026-07-16 11:00 EST — [EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/EYPT/eyepoint-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-daeb0fac) — Source: EyePoint Pharmaceuticals
- 2026-07-13 11:00 EST — [EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer](https://biopharmsignal.com/news/EYPT/eyepoint-appoints-tarek-s-hassan-m-d-as-chief-strategic-science-officer-4900131f) — Source: EyePoint Pharmaceuticals
- 2026-06-16 11:00 EST — [EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/EYPT/eyepoint-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-3aba909d) — Source: EyePoint Pharmaceuticals
- 2026-05-19 11:00 EST — [EyePoint Announces Participation at Upcoming Investor Conferences](https://biopharmsignal.com/news/EYPT/eyepoint-announces-participation-at-upcoming-investor-conferences-cef7e0be) — Source: EyePoint Pharmaceuticals
- 2026-05-18 11:00 EST — [EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/EYPT/eyepoint-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-147957c3) — Source: EyePoint Pharmaceuticals
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)